Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Safety Study of CRB-4001 for the Treatment of Nonalcoholic Steatohepatitis (NASH)/ Nonalcoholic fatty liver disease (NAFLD)

Trial Profile

A Phase I Safety Study of CRB-4001 for the Treatment of Nonalcoholic Steatohepatitis (NASH)/ Nonalcoholic fatty liver disease (NAFLD)

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 12 Feb 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CRB-4001 (Primary)
  • Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
  • Focus Adverse reactions; First in man
  • Sponsors Corbus Pharmaceuticals
  • Most Recent Events

    • 07 Feb 2020 According to an Corbus Pharmaceuticals media release, the company announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock. The company intends to use the net proceeds of the proposed underwritten offering to fund its continued development of CRB-4001 for clinical trials.
    • 11 Nov 2019 According to an Corbus Therapeutics media release, data from this study is expected in 2020.
    • 07 Nov 2019 According to an Corbus Therapeutics media release, this trial is expected to start in 2020.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top